A Milestone: First Patient Dosed in Phase II/III Trial for Core Asset (10/17/2025)

L&L Bio's LB1410 Achieves First CR in Cervical Cancer(11/6/2025)

NMPA approves L&L Bio's first Phase II/III clinical trial(8/06/2025)

Series B financing completed 

(3/20/2023)

Participate in the finals of the China Innovation and Entrepreneurship Competition team category (7/31/2025)

L&L Bio Participates in SAPA 2025 Annual Conference (9/27/2025)

LB1410 in combination with LB4330 Phase I/II NMPA approval

 (3/11/2024)

Attended BIO US 2025 Conference

 (6/16-19/2025)